相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
Mark Nelson et al.
AIDS (2011)
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results
Brian Gazzard et al.
AIDS (2011)
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study)
D. Podzamczer et al.
HIV MEDICINE (2011)
Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results
Paul E. Sax et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
Anton L. Pozniak et al.
AIDS (2010)
Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study
Juan Sierra-Madero et al.
HIV CLINICAL TRIALS (2010)
Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Christine Katlama et al.
AIDS (2009)
Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection
Michael J. Silverberg et al.
ANNALS OF INTERNAL MEDICINE (2009)
Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels
Andrew Hill et al.
HIV CLINICAL TRIALS (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study:: a multi-cohort collaboration
Caroline A. Sabin et al.
LANCET (2008)
Class of antiretroviral drugs and the risk of myocardial infarction
Nina Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome
Kathleen V. Fitch et al.
AIDS (2006)
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients:: comparison with observed events in the D:A:D Study
MG Law et al.
HIV MEDICINE (2006)
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
F van Leth et al.
LANCET (2004)
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
K Squires et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
分享论文
